The following is a summary of “Biomarkers of ocular manifestation in newly diagnosed giant cell arteritis,” published in the ...

The ASRS noted that since approval on 7th October last year there have been 14 cases of vasculitis – inflammation of the blood vessels – with 11 reported to be occlusive retinal vasculitis ...

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for aflibercept injection 8mg for the treatment of macular edema following ...

FDA accepts Regeneron's sBLA for Eylea HD in RVO with priority review; QUASAR data supports monthly dosing, target action date set for August 2025.

retinal vasculitis and vascular, neurological and gastrointestinal involvement. However, some patients still have refractory disease, relapse, sight-threatening eye disease or irreversible organ ...

Specifically, Syfovre has been linked to several cases of retinal vasculitis, some of which were severe enough to block blood flow in the retina, raising the risk of sight loss. Apellis has ...

Regulatory action was based on data from the Phase III QUASAR trial, which demonstrated that Eylea HD dosed every eight weeks ...

The most commonly reported ocular features of infection include: linearly arranged or scattered chorioretinal lesions, anterior uveitis, retinal vasculitis, optic neuritis and vitritis.

There was one case each of endophthalmitis and retinal vasculitis in all EYLEA HD patients, compared to two cases of endophthalmitis and no cases of retinal vasculitis in EYLEA patients.